Manhattan BioSolutions Enters into a Research Collaboration And License Option Agreement with Binghamton University for the New Linker-Payload Technology

NEW YORK, NY / ACCESSWIRE / June 1, 2022 / Manhattan BioSolutions, Inc., an emerging biotechnology company developing new classes of therapeutic biologics for the treatment of advanced and metastatic cancers, today announced a multitarget research and development collaboration and license option agreement with Binghamton University. The collaboration will utilize novel immune-stimulatory linker-payload technology invented at Binghamton University to develop novel antibody-drug conjugates (ADCs) for oncology applications.

The lead investigator is Dr. L. Nathan Tumey, an Assistant Professor in the School of Pharmacy and Pharmaceutical Sciences. Dr. Tumey is a world-class expert in linker-payload chemistry and ADC design, who joined Binghamton University following a long career as a medicinal chemist in the pharmaceutical industry, most recently at Pfizer. Manhattan BioSolutions will have an exclusive option to license global rights for selected linker-payload – antibody combinations targeting distinct tumor-associated antigens.

In addition to the collaboration, Dr Tumey has joined Manhattan BioSolutions’s Scientific Advisory Board.

Dr. Borys Shor, Chief Executive Officer, Manhattan BioSolutions commented: “This agreement comes as we continue to build out our preclinical pipeline of novel biologics. It enables us to combine our proprietary antibodies with non-cytotoxic payloads designed to specifically activate innate immune pathways in hematological or in solid tumorsDue to his expertise in medicinal chemistry, Dr Tumey’s laboratory will be a key partner to bringing innovative linker-payload technology into our development pipeline.”

Dr. Tumey added: “We are excited to be partnering with Manhattan BioSolutions in order to advance a number of innovative preclinical immune-stimulating ADC programs. We believe that the combination of our proprietary ADC technology and Manhattan Biosolution’s novel tumor targeting antibodies will produce candidate medicines with unique biological properties. We are particularly excited about developing non-cytotoxic ADCs that may have an improved safety profile as compared to traditional ADC technology.”

About Manhattan BioSolutions

Manhattan BioSolutions, Inc. is a privately held biotechnology company focused on the development of biologic immunotherapies that target microbial recognition and host defense pathways for the treatment of advanced cancers. The company has established partnerships with the Stony Brook University, The University at Buffalo, INSERM, EVQLV and has been awarded grants by the National Institutes of Health (NIH), the National Science Foundation (NSF), the New Jersey Commission on Science, Innovation and Technology (CSIT) and the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UBCAT). Learn more at

About Binghamton University

Binghamton University, also known as the State University of New York at Binghamton, is one of four doctoral granting research universities in the SUNY system. It is ranked as an “R1” university according to the Carnegie classification, with annual research expenditures exceeding $40 million. The School of Pharmacy and Pharmaceutical Sciences, a research-intensive pharmacy school established in 2016, has rapidly become a hub of health-sciences research for Binghamton University and the Southern Tier of New York.

Contact for investor inquiries:

Jordana Lovett, PhD
Director of Investor Relations
(857) 600-1021